Molecular Imaging and Biology

, Volume 8, Issue 6, pp 348–354 | Cite as

Optimization of Whole-Body Positron Emission Tomography Imaging by Using Delayed 2-Deoxy-2-[F-18]fluoro-d-glucose Injection Following I.V. Insulin in Diabetic Patients

  • Eric Turcotte
  • Michel Leblanc
  • André Carpentier
  • François BénardEmail author
Research Article



High blood glucose levels may decrease the sensitivity of 2-deoxy-2-[F-18]fluoro-d-glucose (FDG)-positron emission tomography (PET). The goal of this study was to assess whether intravenous (i.v.) insulin followed by FDG injection 60 minutes later could decrease the blood glucose level of hyperglycemic patients without altering muscular, liver, or lung FDG uptake.


We evaluated 53 diabetic patients with a fasting glycemia higher than 7.0 mmol/l. The control group consisted of 53 nondiabetic patients with a normal fasting glycemia. Sixty minutes before FDG injection, all diabetic patients received up to two intravenous bolus of insulin. Regions of interest were drawn over the lungs, heart, liver, skeletal muscles, and over the most active lung nodule, if present, to calculate a standardized uptake value (SUV) normalized to the lean body weight.


After one or two boluses of insulin (mean 3.4 units), 39 diabetic patients decreased their blood glucose level from 9.4 ± 1.8 to 6.1 ± 1.3 mmol/l. In 14 patients, two doses of insulin (mean 4.5 ± 2.3 units) were not sufficient, but managed to decrease the blood glucose level from 10.6 ± 2.1 to 9.1 ± 2.1 mmol/l. There was no significant difference for the SUV calculated on the lung, liver, heart, and skeletal muscles. No differences were noted in lung tumor uptake in patients who received insulin compared to the control group.


With a sufficient waiting period between the insulin and FDG injections, an i.v. bolus of insulin makes it possible to effectively decrease glycemia of diabetic patients without increasing muscular FDG uptake.

Key words

FDG Glucose Insulin Diabetes 


  1. 1.
    Hustinx R, Benard F, Alavi A (2002) Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32(1):35–46CrossRefPubMedGoogle Scholar
  2. 2.
    Diederichs CG, Staib L, Glatting G, et al. (1998) FDG-PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39(6):1030–1033PubMedGoogle Scholar
  3. 3.
    Lindholm P, Minn H, Leskinen-Kallio S, et al. (1993) Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. J Nucl Med 34(1):1–6PubMedGoogle Scholar
  4. 4.
    Torizuka T, Fisher SJ, Brown RS, et al. (1998) Effect of insulin on uptake of FDG by experimental mammary carcinoma in diabetic rats. Radiology 208(2):499–504PubMedGoogle Scholar
  5. 5.
    Wahl RL, Henry CA, Ethier SP (1992) Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-d-glucose in rodents with mammary carcinoma. Radiology 183(3):643–647PubMedGoogle Scholar
  6. 6.
    Lewis P, Nunan T, Dynes A, et al. (1996) The use of low-dose intravenous insulin in clinical myocardial F-18 FDG-PET scanning. Clin Nucl Med 21(1):15–18CrossRefPubMedGoogle Scholar
  7. 7.
    Sherwin RS, Kramer KJ, Tobin JD, et al. (1974) A model of the kinetics of insulin in man. J Clin Invest 53(5):1481–1492PubMedCrossRefGoogle Scholar
  8. 8.
    Morgan DJ, Bray KM (1994) Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 26(4):292–307PubMedGoogle Scholar
  9. 9.
    Medina RA, Owen GI (2002) Glucose transporters: expression, regulation and cancer. Biol Res 35(1):9–26PubMedCrossRefGoogle Scholar
  10. 10.
    Marom EM, Aloia TA, Moore MB, et al. (2001) Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 33(2–3):99–107CrossRefPubMedGoogle Scholar
  11. 11.
    Langen KJ, Braun U, Rota Kops E, et al. (1993) The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 34(3):355–359PubMedGoogle Scholar
  12. 12.
    Crippa F, Gavazzi C, Bozzetti F, et al. (1997) The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas. Tumori 83(4):748–752PubMedGoogle Scholar
  13. 13.
    Torizuka T, Zasadny KR, Wahl RL (1999) Diabetes decreases FDG accumulation in primary lung cancer. Clin Positron Imaging 2(5):281–287CrossRefPubMedGoogle Scholar
  14. 14.
    Gorenberg M, Hallett WA, O’Doherty MJ (2002) Does diabetes affect [(18)F]FDG standardised uptake values in lung cancer? Eur J Nucl Med Mol Imaging 29(10):1324–1327CrossRefPubMedGoogle Scholar
  15. 15.
    Chang YC, Yen TC, Ng KK, et al. (2005) Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer? Eur J Nucl Med Mol Imaging 32(6):647–652CrossRefPubMedGoogle Scholar
  16. 16.
    Torizuka T, Fisher SJ, Wahl RL (1997) Insulin-induced hypoglycemia decreases uptake of 2-[F-18]fluoro-2-deoxy-d-glucose into experimental mammary carcinoma. Radiology 203(1):169–172PubMedGoogle Scholar
  17. 17.
    Zhao S, Kuge Y, Tsukamoto E, et al. (2001) Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med 28(6):730–735CrossRefPubMedGoogle Scholar

Copyright information

© Academy of Molecular Imaging 2006

Authors and Affiliations

  • Eric Turcotte
    • 1
  • Michel Leblanc
    • 1
  • André Carpentier
    • 2
  • François Bénard
    • 1
    Email author
  1. 1.Sherbrooke Molecular Imaging Center (CIMS)Centre Hospitalier Universitaire de SherbrookeSherbrookeCanada
  2. 2.Division of Endocrinology and metabolism, Department of Medicine, Clinical Research CenterCentre Hospitalier Universitaire de SherbrookeSherbrookeCanada

Personalised recommendations